Physician profile

Amanda Brenner

Geriatric Medicine (Family Medicine) · Jacksonville, FL

NPI 1104445113

$561.20

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$382.45

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Otsuka America Pharmaceutical, INC. $217.66 2023-2024 Rexulti
Amgen INC. $150.00 2024 Tepezza
Boehringer Ingelheim Pharmaceuticals, INC. $89.30 2022
Gilead Sciences, INC. $44.57 2020
Novo Nordisk INC $16.69 2022
Xeris Pharmaceuticals, INC. $15.77 2020
Exact Sciences Corporation $14.79 2023 Cologuard Collection Kit
Merck Sharp & Dohme LLC $12.42 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Amanda Brenner

$561.20

in general payments reported 2019-2025

Years
2020-2024
Top company
Otsuka America Pharmaceutical, INC.

https://glasscript.com/doctor/8801313/amanda-brenner

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.